HONG KONG MEDICAL JOURNAL 香港醫學雜誌

Supplementary material

The supplementary material was provided by the authors and some information may not have been peer reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by the Hong Kong Academy of Medicine and the Hong Kong Medical Association. The Hong Kong Academy of Medicine and the Hong Kong Medical Association disclaim all liability and responsibility arising from any reliance placed on the content.

Supplement to: DTH Chan, LHP Tam, TTO Lam, et al. Prevalence, risk factors, and outcomes of systemic sclerosis–associated interstitial lung disease in a Chinese population. Hong Kong Med J 2025 Feb;31(1):16-23 | Epub 12 Feb 2025. https://doi.org/10.12809/hkmj2411807.

Supplementary Figure. Kaplan–Meier curve for cumulative survival in patients with and without interstitial lung disease (ILD)



Log-rank test, P=0.056

Supplementary Table 1. Clinical characteristics of systemic sclerosis patients with and without interstitial lung disease*

	With ILD (n=111)	Without ILD (n=112)	Total (n=223)	P value
Clinical features				
Raynaud's phenomenon				
On presentation	94 (84.7%)	97 (86.6%)	191 (85.7%)	0.682
On follow-up	11 (9.9%)	7 (6.3%)	18 (8.1%)	0.316
Ever had	105 (94.6%)	104 (92.9%)	209 (93.7%)	0.593
Puffy fingers				
On presentation	19 (17.1%)	22 (19.6%)	41 (18.4%)	0.626
On follow-up	8 (7.2%)	14 (12.5%)	22 (9.9%)	0.185
Ever had	27 (24.3%)	36 (32.1%)	63 (28.3%)	0.195
Sclerodactyly				
On presentation	84 (75.7%)	79 (70.5%)	163 (73.1%)	0.387
On follow-up	20 (18.0%)	25 (22.3%)	45 (20.2%)	0.423
Ever had	104 (93.7%)	104 (92.9%)	208 (93.3%)	0.803
Digital ulcers				
On presentation	15 (13.5%)	14 (12.5%)	29 (13.0%)	0.822
On follow-up	22 (19.8%)	16 (14.3%)	38 (17.0%)	0.272
Ever had	37 (33.3%)	30 (26.8%)	67 (30.0%)	0.286
Oesophageal dysmotility				
On presentation	27 (24.3%)	23 (20.5%)	50 (22.4%)	0.498
On follow-up	42 (37.8%)	35 (31.3%)	77 (34.5%)	0.301
Ever had	69 (62.2%)	58 (51.8%)	127 (57.0%)	0.118
Arthralgia				
On presentation	33 (29.7%)	36 (32.1%)	69 (30.9%)	0.697
On follow-up	19 (17.1%)	16 (14.3%)	35 (15.7%)	0.561
Ever had	52 (46.8%)	52 (46.4%)	104 (46.6%)	0.95
Dyspnoea				
On presentation	36 (32.4%)	5 (4.5%)	41 (18.4%)	<0.001

On follow-up	52 (46.8%)	11 (9.8%)	63 (28.3%)	<0.001
Ever had	88 (79.3%)	16 (14.3%)	104 (46.6%)	<0.001
Cough				
On presentation	15 (13.5%)	1 (0.9%)	16 (7.2%)	<0.001
On follow-up	27 (24.3%)	4 (3.6%)	31 (13.9%)	<0.001
Ever had	42 (37.8%)	5 (4.5%)	47 (21.1%)	<0.001
Bibasal crackles				
On presentation	26 (23.4%)	3 (2.7%)	29 (13.0%)	<0.001
On follow-up	50 (45.0%)	4 (3.6%)	54 (24.2%)	<0.001
Ever had	76 (68.5%)	7 (6.3%)	83 (37.2%)	<0.001
Pulmonary hypertension				
On presentation	1 (0.9%)	1 (0.9%)	2 (0.9%)	1
On follow-up	21 (18.9%)	2 (1.8%)	23 (10.3%)	<0.001
Ever had	22 (19.8%)	3 (2.7%)	25 (11.2%)	<0.001
Laboratory results				
CRP at baseline, mg/L	1.2 (1-3.93)	1.7 (1-3.2)	1.5 (1-3.25)	0.656
ESR at baseline, mm/hr	21.5 (14-40.5)	18 (11-30)	20 (12-32.5)	0.074

Abbreviations: CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; ILD = interstitial lung disease

[*] Data are shown as No. (%) or median (interquartile range), unless otherwise specified

Supplementary Table 2. Univariable and multivariable Cox regression for predictors of interstitial lung disease

	Univariable analysis		Multivariable analysis*	
	Hazard ratio (95% CI)	**P value**	**Hazard ratio (95% CI)**	**P value**
dcSSc	2.039 (1.381- 3.067)	<0.001		
lcSSc	0.491 (0.326-0.724)	<0.001		
ATA	2.048 (1.383-3.077)	<0.001		
ACA	0.199 (0.087-0.452)	<0.001		
Ever had dyspnoea	3.645 (2.242-5.988)	<0.001	1.943 (0.978-3.861)	0.058
Ever had cough	2.177 (1.464-3.300)	<0.001		
Ever had bibasal crackles	3.726 (2.457-5.714)	<0.001	2.813 (1.540-5.181)	0.001
Ever had PH†	2.413 (1.477-3.861)	<0.001		
Baseline ESR	1.013 (1.003-1.023)	0.012		

Abbreviations: 95% CI = 95% confidence interval; ACA = anti-centromere antibody; ATA = anti-topoisomerase antibody; dcSSc = diffuse cutaneous systemic sclerosis; ESR = erythrocyte sedimentation rate; lcSSc = limited cutaneous systemic sclerosis; PH = pulmonary hypertension

* Included variables with P<0.05 in univariable analyses (dcSSc, ATA, ever had dyspnoea, ever had cough, ever had bibasal crackles, and baseline ESR)

† Excluded as it was likely a consequence of underlying interstitial lung disease

Supplementary Table 3. Baseline characteristics of systemic sclerosis patients with progressive and non-progressive interstitial lung disease in this study*

	Progressive ILD (n=59)	Non-progressive ILD (n=33)	Total (n=92)	P value
Female sex	51 (86.4%)	29 (87.9%)	80 (87.0%)	0.844
Age, y [mean (range)]	63.6 (26-97)	64.8 (35-94)	64.1 (26-97)	0.654
Smoking history				
Never	51 (86.4%)	29 (87.9%)	80 (87.0%)	0.844
Ex-smoker	6 (10.2%)	0	6 (6.5%)	0.084
Current smoker	0	2 (6.1%)	2 (2.2%)	0.126
Ever smoker	6 (10.2%)	2 (6.1%)	8 (8.7%)	0.707
Disease duration, y	11.6 (8.1-15.5)	9.8 (5-19.7)	10.5 (6.5-16.3)	0.928
Age at SSc diagnosis, y	53 (20-81)	56 (20-79)	54 (20-81)	0.401
Age at ILD diagnosis, y	54 (20-85)	60 (31-81)	57 (20-85)	0.051
dcSSc	22 (37.3%)	13 (39.4%)	35 (38.0%)	0.842
lcSSc	36 (61.0%)	20 (60.6%)	56 (60.9%)	0.969
Autoantibodies				
ATA	37 (62.7%)	18 (54.5%)	55 (59.8%)	0.444
ACA	2 (3.4%)	2 (6.1%)	4 (4.3%)	0.616
RNP	10 (16.9%)	3 (9.1%)	13 (14.1%)	0.365

Abbreviations: ACA = anti-centromere antibody; ATA = anti-topoisomerase antibody; dcSSc = diffuse cutaneous systemic sclerosis; ILD = interstitial lung disease; lcSSc = limited cutaneous systemic sclerosis; RNP = ribonucleoprotein antibody; SSc = systemic sclerosis

* Data are shown as No. (%) or median (interquartile range), unless otherwise specified

Supplementary Table 4. Clinical characteristics of systemic sclerosis patients with progressive and non-progressive interstitial lung disease*

	Progressive ILD (n=59)	Non-progressive ILD (n=33)	Total (n=92)	P value
Raynaud's phenomenon				
On presentation	52 (88.1%)	26 (78.8%)	78 (84.8%)	0.231
On follow-up	3 (5.1%)	5 (15.2%)	8 (8.7%)	0.130
Ever had	55 (93.2%)	31 (93.9%)	86 (93.5%)	0.893
Puffy fingers				
On presentation	11 (18.6%)	6 (18.2%)	17 (18.5%)	0.956
On follow-up	5 (8.5%)	1 (3.0%)	6 (6.5%)	0.414
Ever had	16 (27.1%)	7 (21.2%)	23 (25.0%)	0.530
Sclerodactyly				
On presentation	43 (72.9%)	26 (78.8%)	69 (75.0%)	0.530
On follow-up	11 (18.6%)	5 (15.2%)	16 (17.4%)	0.672
Ever had	54 (91.5%)	31 (93.9%)	85 (92.4%)	0.675
Digital ulcers				
On presentation	11 (18.6%)	4 (12.1%)	15 (16.3%)	0.417
On follow-up	14 (23.7%)	1 (3.0%)	15 (16.3%)	0.010
Ever had	25 (42.4%)	5 (15.2%)	30 (32.6%)	0.008
Oesophageal dysmotility				
On presentation	14 (23.7%)	11 (33.3%)	25 (27.2%)	0.321
On follow-up	25 (42.4%)	10 (30.3%)	35 (38.0%)	0.273
Ever had	39 (66.1%)	21 (63.6%)	60 (65.2%)	0.812
Arthralgia				
On presentation	15 (25.4%)	11 (33.3%)	26 (28.3%)	0.419
On follow-up	13 (22.0%)	4 (12.1%)	17 (18.5%)	0.240
Ever had	28 (47.5%)	15 (45.5%)	43 (46.7%)	0.853
Dyspnoea				
On presentation	18 (30.5%)	15 (45.5%)	33 (35.9%)	0.152
On follow-up	31 (52.5%)	11 (33.3%)	42 (45.7%)	0.076
Ever had	49 (83.1%)	26 (78.8%)	75 (81.5%)	0.613
Cough				
On presentation	8 (13.6%)	5 (15.2%)	13 (14.1%)	1
On follow-up	17 (28.8%)	5 (15.2%)	22 (23.9%)	0.141
Ever had	25 (42.4%)	10 (30.3%)	35 (38.0%)	0.253
Bibasal crackles				
On presentation	15 (25.4%)	9 (27.3%)	24 (26.1%)	0.846
On follow-up	29 (49.2%)	11 (33.3%)	40 (43.5%)	0.142
Ever had	44 (74.6%)	20 (60.6%)	64 (69.6%)	0.162
Pulmonary hypertension				
On presentation	0	1 (3.0%)	1 (1.1%)	0.359
On follow-up	14 (23.7%)	4 (12.1%)	18 (19.6%)	0.178
Ever had	14 (23.7%)	5 (15.2%)	19 (20.7%)	0.330

Abbreviation: ILD = interstitial lung disease

* Data are shown as No. (%), unless otherwise specified

Supplementary Table 5. Causes of death among systemic sclerosis patients in this study*[*]

	With ILD (n=33)	Without ILD (n=21)	Total (n=54)
Infection			31 (57.4%)
Pneumonia	21 (63.6%)	9 (42.9%)	30 (55.6%)
Unknown source	N/A	1 (4.8%)	1 (1.9%)
Malignancy			12 (22.2%)
Lung	4 (12.1%)	4 (19.0%)	8 (14.8%)
Colon	N/A	1 (4.8%)	1 (1.9%)
Corpus	1 (3.0%)	N/A	1 (1.9%)
Lymphoma	N/A	2 (9.5%)	2 (3.7%)
SSc-related			5 (9.3%)
ILD	4 (12.1%)	N/A	4 (7.4%)
PH	N/A	1 (4.8%)	1 (1.9%)
Others			6 (11.1%)
Cardiovascular	1 (3.0%)	1 (4.8%)	2 (3.7%)
End-stage renal failure	N/A	1 (4.8%)	1 (1.9%)
Unknown	2 (6.1%)	1 (4.8%)	3 (5.6%)

Abbreviations: ILD = interstitial lung disease; N/A = not applicable; PH = pulmonary hypertension; SSc = systemic sclerosis

[*] Data are shown as No. (%)